Advances in the Understanding of Oxaliplatin-Induced Peripheral Neuropathy in Mice: 7-Chloro-4-(Phenylselanyl) Quinoline as a Promising Therapeutic Agent

Reis, Angélica S.; Paltian, Jaini J.; Domingues, William Borges; Novo, Diogo La Rosa; Costa, Gabriel P.; Alves, Diego; Campos, Vinicius F.; Mesko, Márcia F.; Luchese, Cristiane; Wilhelm, Ethel A.

doi:10.1007/s12035-020-02048-4

Cited by 14 publications

(10 citation statements)

References 64 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These results corroborate another study carried out by our research group, in which 4-PSQ also reversed the mechanical and thermal hypersensitivities induced by chemotherapeutic OXA exposure. 21 By considering that OXA and STZ can cause neuropathy through oxidative stress, 63,64 4-PSQ has proven to be highly promising in modulating this mechanism, regardless of the experimental model. In fact, our research group has dedicated special attention to studying and identifying new agents capable of reducing and treating the symptoms of pathologies involving oxidative stress.…”

Section: Discussionmentioning

confidence: 99%

“…The dose and protocol of 4-PSQ treatment were based on previous research. 12,26 Since other pre-clinical studies evaluating the pharmacological actions of the 4-PSQ have been carried out, 13,14,[16][17][18][19][20][21]26,27 a dose-response curve was not performed to minimize the number of animals used.…”

Section: Experimental Designmentioning

confidence: 99%

“…17 Data obtained by our research group suggested that 4-PSQ is an excellent prototype for developing a more effective drug to treat oxaliplatin (OXA)-induced peripheral neuropathy. 21 In fact, Reis et al (2020) 21 provided solid evidence that 4-PSQ can reduce anxious behavior and OXA-induced cognitive impairment. It is also worth noting that 4-PSQ did not show toxicity in mice.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Contribution of antioxidant action of 7-chloro-4-(phenylselanyl)quinoline to treat streptozotocin-induced diabetic neuropathy in mice

et al. 2022

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Experimental Designmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Contribution of antioxidant action of 7-chloro-4-(phenylselanyl)quinoline to treat streptozotocin-induced diabetic neuropathy in mice

et al. 2022

View full text Add to dashboard Cite

show abstract

“…Nanotechnology is not only inspired by virology to develop novel therapeutics and vaccines, but also at the forefront in combatting dangerous viruses ( Reis et al., 2020 ; Hu et al., 2021 ; An et al., 2021 ; Lee et al., 2022 ). However, up to date, there is still a long way to go to develop B19V-tailored nanosystems.…”

Section: Nanosystemsmentioning

confidence: 99%

Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19

Chen

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

Parvovirus B19 (B19V) as a human pathogenic virus, would cause a wide range of clinical manifestations. Besides the supportive and symptomatic treatments, the only FDA-approved antiviral drug for the treatment of B19V is intravenous immunoglobulins, which however, have limited efficacy and high cost. By far, there are still no virus-specific therapeutics clinically available to treat B19V infection. Therefore, exploiting the potential targets with a deep understanding of the life cycle of B19V, are pivotal to the development of B19V-tailored effective antiviral approaches. This review will introduce antiviral agents via blocking viral invasion, inhibiting the enzymes or regulatory proteins involved in DNA synthesis, and so on. Moreover, nanotechnology-enabled approaches against B19V will also be outlined and discussed through a multidisciplinary perspective involving virology, nanotechnology, medicine, pharmaceutics, chemistry, materials science, and other fields. Lastly, the prospects of the antiviral agents and nanosystems in terms of fabrication, clinical translation and potential breakthroughs will be briefly discussed.

show abstract

“…Besides, 7-chloro-4-(phenylselanyl) quinoline (4-PSQ) with antinociceptive, antioxidant, and neuroprotective effects has also been studied. As reported, 4-PSQ (1 mg/kg, p.o., days 2–14) not only reversed the increased levels of ROS in the spinal cord, cerebral cortex, and hippocampus, but also normalized the activity and expression of antioxidant enzymes [e.g., CAT, SOD, and glutathione peroxidase (GPx)] and acetylcholinesterase (AChE) in OXA-exposed mice ( Reis et al, 2020 ). In addition, donepezil (1 mg/kg, p.o., five times per week for 4 weeks) could ameliorate OXA-induced mechanical allodynia and sciatic nerve axonal degeneration in a rat model, whose neuroprotective effect was attributed to its free-radical scavenging ability ( Kawashiri et al, 2019 ).…”

Section: Therapeutic Strategies Of Platinum-induced Peripheral Neuropathymentioning

confidence: 99%

Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems

Jiang

Teng

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Platinum (Pt) drugs (e.g., oxaliplatin, cisplatin) are applied in the clinic worldwide for the treatment of various cancers. However, platinum-induced peripheral neuropathy (PIPN) caused by the accumulation of Pt in the peripheral nervous system limits the clinical application, whose prevention and treatment are still a huge challenge. To date, Pt-induced reactive oxygen species (ROS) generation has been studied as one of the primary mechanisms of PIPN, whose downregulation would be feasible to relieve PIPN. This review will discuss ROS-related PIPN mechanisms including Pt accumulation in the dorsal root ganglia (DRG), ROS generation, and cellular regulation. Based on them, some antioxidant therapeutic drugs will be summarized in detail to alleviate the Pt-induced ROS overproduction. More importantly, we focus on the cutting-edge nanotechnology in view of ROS-related PIPN mechanisms and will discuss the rational fabrication of tailor-made nanosystems for efficiently preventing and treating PIPN. Last, the future prospects and potential breakthroughs of these anti-ROS agents and nanosystems will be briefly discussed.

show abstract

Advances in the Understanding of Oxaliplatin-Induced Peripheral Neuropathy in Mice: 7-Chloro-4-(Phenylselanyl) Quinoline as a Promising Therapeutic Agent

Cited by 14 publications

References 64 publications

Contribution of antioxidant action of 7-chloro-4-(phenylselanyl)quinoline to treat streptozotocin-induced diabetic neuropathy in mice

Contribution of antioxidant action of 7-chloro-4-(phenylselanyl)quinoline to treat streptozotocin-induced diabetic neuropathy in mice

Towards the Antiviral Agents and Nanotechnology-Enabled Approaches Against Parvovirus B19

Platinum-Induced Peripheral Neuropathy (PIPN): ROS-Related Mechanism, Therapeutic Agents, and Nanosystems

Contact Info

Product

Resources

About